These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33835391)

  • 21. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.
    Keskin AU; Bolukcu S; Ciragil P; Topkaya AE
    J Med Virol; 2022 Jan; 94(1):39-41. PubMed ID: 34536028
    [No Abstract]   [Full Text] [Related]  

  • 22. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.
    Corbett KS; Nason MC; Flach B; Gagne M; O'Connell S; Johnston TS; Shah SN; Edara VV; Floyd K; Lai L; McDanal C; Francica JR; Flynn B; Wu K; Choi A; Koch M; Abiona OM; Werner AP; Moliva JI; Andrew SF; Donaldson MM; Fintzi J; Flebbe DR; Lamb E; Noe AT; Nurmukhambetova ST; Provost SJ; Cook A; Dodson A; Faudree A; Greenhouse J; Kar S; Pessaint L; Porto M; Steingrebe K; Valentin D; Zouantcha S; Bock KW; Minai M; Nagata BM; van de Wetering R; Boyoglu-Barnum S; Leung K; Shi W; Yang ES; Zhang Y; Todd JM; Wang L; Alvarado GS; Andersen H; Foulds KE; Edwards DK; Mascola JR; Moore IN; Lewis MG; Carfi A; Montefiori D; Suthar MS; McDermott A; Roederer M; Sullivan NJ; Douek DC; Graham BS; Seder RA
    Science; 2021 Sep; 373(6561):eabj0299. PubMed ID: 34529476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.
    Tscherne A; Schwarz JH; Rohde C; Kupke A; Kalodimou G; Limpinsel L; Okba NMA; Bošnjak B; Sandrock I; Odak I; Halwe S; Sauerhering L; Brosinski K; Liangliang N; Duell E; Jany S; Freudenstein A; Schmidt J; Werner A; Gellhorn Serra M; Klüver M; Guggemos W; Seilmaier M; Wendtner CM; Förster R; Haagmans BL; Becker S; Sutter G; Volz A
    Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34162739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
    Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
    JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
    Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
    J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates.
    He Q; Mao Q; Peng X; He Z; Lu S; Zhang J; Gao F; Bian L; An C; Yu W; Yang F; Zhou Y; Yang Y; Li Y; Yuan Y; Yan X; Yang J; Wu X; Huang W; Li C; Wang J; Liang Z; Xu M
    Signal Transduct Target Ther; 2022 Mar; 7(1):69. PubMed ID: 35241645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
    Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
    Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.
    Zhou X; Wang H; Ji Q; Du M; Liang Y; Li H; Li F; Shang H; Zhu X; Wang W; Jiang L; Stepanov AV; Ma T; Gong N; Jia X; Gabibov AG; Lou Z; Lu Y; Guo Y; Zhang H; Yang X
    Protein Cell; 2021 Oct; 12(10):818-823. PubMed ID: 33909239
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety and potency of BIV1-CovIran inactivated vaccine candidate for SARS-CoV-2: A preclinical study.
    Abdoli A; Aalizadeh R; Aminianfar H; Kianmehr Z; Teimoori A; Azimi E; Emamipour N; Eghtedardoost M; Siavashi V; Jamshidi H; Hosseinpour M; Taqavian M; Jalili H
    Rev Med Virol; 2022 May; 32(3):e2305. PubMed ID: 34699647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies.
    Wang X; Zhao X; Song J; Wu J; Zhu Y; Li M; Cui Y; Chen Y; Yang L; Liu J; Zhu H; Jiang S; Wang P
    Emerg Microbes Infect; 2022 Dec; 11(1):477-481. PubMed ID: 35034583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates.
    Mukhopadhyay L; Yadav PD; Gupta N; Mohandas S; Patil DY; Shete-Aich A; Panda S; Bhargava B
    Indian J Med Res; 2021 Jan & Feb; 153(1 & 2):93-114. PubMed ID: 33361645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19.
    Tran TNM; May BP; Ung TT; Nguyen MK; Nguyen TTT; Dinh VL; Doan CC; Tran TV; Khong H; Nguyen TTT; Hua HQH; Nguyen VA; Ha TP; Phan DL; Nguyen TA; Bui TN; Tu TM; Nguyen TT; Le TTH; Dong TL; Huynh TH; Ho PH; Le NTT; Truong CT; Pham HP; Luong CY; Y NL; Cao MN; Nguyen DK; Le TT; Vuong DC; Nguyen LKH; Do MS
    Front Immunol; 2021; 12():766112. PubMed ID: 34938290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.
    Wang H; Zhang Y; Huang B; Deng W; Quan Y; Wang W; Xu W; Zhao Y; Li N; Zhang J; Liang H; Bao L; Xu Y; Ding L; Zhou W; Gao H; Liu J; Niu P; Zhao L; Zhen W; Fu H; Yu S; Zhang Z; Xu G; Li C; Lou Z; Xu M; Qin C; Wu G; Gao GF; Tan W; Yang X
    Cell; 2020 Aug; 182(3):713-721.e9. PubMed ID: 32778225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective Immunity against Gamma and Zeta Variants after Inactivated SARS-CoV-2 Virus Immunization.
    Fumagalli MJ; Castro-Jorge LA; Fraga-Silva TFC; de Azevedo PO; Capato CF; Rattis BAC; Hojo-Souza NS; Floriano VG; de Castro JT; Ramos SG; da Fonseca BAL; Bonato VLD; Gazzinelli RT; Figueiredo LTM
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates.
    van Doremalen N; Fischer RJ; Schulz JE; Holbrook MG; Smith BJ; Lovaglio J; Petsch B; Munster VJ
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
    Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
    J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
    Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
    J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.
    Huang X; Yan Y; Su B; Xiao D; Yu M; Jin X; Duan J; Zhang X; Zheng S; Fang Y; Zhang T; Tang W; Wang L; Wang Z; Xu J
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques.
    Li Y; Bi Y; Xiao H; Yao Y; Liu X; Hu Z; Duan J; Yang Y; Li Z; Li Y; Zhang H; Ding C; Yang J; Li H; He Z; Liu L; Hu G; Liu S; Che Y; Wang S; Li Q; Lu S; Cun W
    Emerg Microbes Infect; 2021 Dec; 10(1):342-355. PubMed ID: 33555988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.